32
Participants
Start Date
July 31, 2004
Primary Completion Date
October 31, 2008
Study Completion Date
December 31, 2008
NV1020
NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
University of Pittsburgh Cancer Center, Pittsburgh
University of Vanderbilt, Nashville
Mary Crowley Medical Research Center, Dallas
University of California, San Diego, San Diego
Massachusetts General Hospital, Boston
Lead Sponsor
MediGene
INDUSTRY